David Robert Spigel
Sarah Cannon
Affiliation Sarah Cannon Top Publications Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (2012) – 12,882 citations Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer (2015) – 9,582 citations Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (2015) – 8,653 citations Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC ... <a title="David Robert Spigel" class="read-more" href="https://journalsworld.com/researchers/david-robert-spigel/" aria-label="Read more about David Robert Spigel">Read more</a>
Read biography ↓Biography, research & contributions
Affiliation
Sarah Cannon
Top Publications
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (2012) - 12,882 citations
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer (2015) - 9,582 citations
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (2015) - 8,653 citations
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC (2018) - 2,862 citations
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial (2019) - 2,325 citations
At a glance
- Full name
- David Robert Spigel
- ORCID
- 0000-0003-3215-9465
- OpenAlex ID
- https://openalex.org/A5018054038
Research interests
- Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics
Research topics
Education
Not yet documented in this profile.
Selected research & further reading
A curated reading list, not a ranking by citation count. References use DOI metadata, matching public scholarly records or authoritative lecture sources.
See the source-linked reading and original works in the research guide above.
Citation & publication trends
Annual counts are not yet available from a verified author record. Explore the research guide above for the work itself; publication and citation totals depend on database coverage.
Source: OpenAlex · Retrieved 2026-10-07. Metrics are database-specific and are not a scientific ranking.
Most-cited linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer ↗2012 · New England Journal of Medicine12,882OpenAlex citations
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer ↗2015 · New England Journal of Medicine9,582OpenAlex citations
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer ↗2015 · New England Journal of Medicine8,653OpenAlex citations
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC ↗2018 · New England Journal of Medicine2,862OpenAlex citations
- 2,325OpenAlex citations
Recent linked publications
Publications matched across ORCID and OpenAlex. Citation counts are source-specific.
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer ↗2012 · New England Journal of Medicine
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer ↗2015 · New England Journal of Medicine
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer ↗2015 · New England Journal of Medicine
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC ↗2018 · New England Journal of Medicine
Journals published in
No verified record links added yet.
Related publishers
No verified record links added yet.
Institutions
Current verified institution
No verified record links added yet.
Previous institutions
No verified record links added yet.
Awards & honors
Not yet documented in this profile.
Career timeline
Not yet documented in this profile.
Co-authors
No verified record links added yet.
Education & career institution links
No verified record links added yet.
Claim & manage this profile
Are you this researcher? Sign in, provide identity evidence, and request administrator approval. Editing becomes available only after approval.
Sign in to claim this profileSources & data information
Editorial review: 2026-10-07 · Last data update: 2026-10-07 21:18:50
Unknown values are left blank. Linked publications may be a subset of total works. Identity verification, data retrieval and profile ownership are separate checks.